MedTrace Logo

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

NCT00551135 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 425

Last updated 2021-01-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.

Conditions

  • Pain, Postoperative
  • Hernia, Inguinal

Interventions

DRUG

Pregabalin

150 mg BID

DRUG

placebo

Placebo

DRUG

Pregabalin

75 mg BID

DRUG

Pregabalin

25 mg BID

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • United States
  • Australia
  • Canada
  • India
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00551135 on ClinicalTrials.gov